ST诺泰(688076.SH)：通过药品GMP符合性检查

Core Viewpoint - ST诺泰's subsidiary, Hangzhou Ausino Biotechnology Co., Ltd., has successfully passed the GMP compliance inspection for its active pharmaceutical ingredient, Aogtewei Sodium, marking a significant milestone in its production capabilities and quality management system [1] Group 1: Company Achievements - The company received the GMP compliance inspection notice from the Zhejiang Provincial Drug Administration, indicating its adherence to high production standards [1] - The successful inspection reinforces the company's commitment to "time-leading and technology-leading" operational philosophy [1] - The achievement is pivotal for the company's CDMO business, extending its value from high-level intermediates to active pharmaceutical ingredients [1] Group 2: Industry Implications - The compliance with GMP standards is expected to positively impact the company's ability to attract innovative pharmaceutical clients [1] - This milestone reflects the company's competitive edge in the pharmaceutical manufacturing sector, particularly in the production of innovative drug raw materials [1]